“…Thus, the subset of upregulated genes will show a relative enrichment of promoter TFBMs for the activated TF (for example, CREB) relative to that observed in a control set of genes (for example, the basal prevalence across all genes in a genome, or TFBM prevalence in a parallel derived set of downregulated genes, which better controls for the fact that about half of the genome is not expressible in any given cell type because of intrinsic variations in the transcriptional basis for cell development and differentiation). In the present study, we conducted such promoter TFBM enrichment analyses to test a series of a priori theories regarding the transcription control pathways that may be activated in the context of MDD, including the CREB/ATF family, 18 , 22 the GR, 25 , 26 , 27 , 28 , 29 , 30 , 50 , 51 , 52 EGR family TFs, 31 , 32 , 33 , 34 the nuclear factor kappa-B cell (NF-κB)/Rel family of TFs that mediate signaling by many pro-inflammatory cytokines, 36 , 37 , 39 , 40 interferon regulatory factor (IRF) family TFs that mediate signaling by Type I interferons 37 , 41 , 42 , 43 , 53 and the nuclear factor erythroid-derived 2-like 2 (NRF2) TF that mediates transcriptional responses to oxidative stress. 40 , 44 , 45 , 46 …”